• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form FWP filed by Novartis AG

    11/3/25 8:59:48 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NVS alert in real time by email
    FWP 1 tm2529850d3_fwp.htm FWP

     

    Filed Pursuant to Rule 433

    Registration Nos. 333-282133 and 333-282133-01

    November 3, 2025

     

     

    PRICING TERM SHEET

     

    Novartis Capital Corporation

     

    3.900% Notes due 2028

     

    4.100% Notes due 2030

     

    4.300% Notes due 2032

     

    4.600% Notes due 2035

     

    5.200% Notes due 2045

     

    5.300% Notes due 2055

     

    Floating Rate Notes due 2028

     

    Fully and unconditionally guaranteed by

     

    Novartis AG

     

    3.900% Notes due 2028 (the “2028 Notes”):  
       
    Issuer: Novartis Capital Corporation
       
    Guarantor: Novartis AG
       
    Size: $700,000,000
       
    Maturity Date: November 5, 2028
       
    Coupon: 3.900%
       
    Interest Payment Dates: May 5 and November 5, commencing May 5, 2026
       
    Price to Public: 99.978%
       
    Benchmark Treasury: 3.500% due October 15, 2028

     

    1

     

     

    Benchmark Treasury Price and Yield: 99-22 3/8 / 3.608%
       
    Spread to Benchmark Treasury: 30 bps
       
    Yield: 3.908%
       
    Optional Redemption: Prior to October 5, 2028 (the date that is one month prior to the scheduled maturity date of the 2028 Notes) (the “2028 Par Call Date”), we may redeem the 2028 Notes, in whole or in part, at our option, at any time and from time to time at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:
       
        (1) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the 2028 Notes matured on the 2028 Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in the prospectus supplement) plus 5 bps, less (b) interest accrued to the date of redemption, and
       
        (2) 100% of the principal amount of the 2028 Notes to be redeemed,
       
      plus, in either case, accrued and unpaid interest thereon to the redemption date.
       
      On or after the 2028 Par Call Date we may redeem the 2028 Notes, in whole or in part, at any time and from time to time at a redemption price equal to 100% of the principal amount of the 2028 Notes to be redeemed on the applicable redemption date plus accrued and unpaid interest thereon to the redemption date.
       
    Optional Redemption for Tax Reasons: In the event of changes in withholding taxes applicable to payments under or with respect to the 2028 Notes or certain intercompany loans in Switzerland or another Relevant Taxing Jurisdiction (as defined and provided for in the prospectus supplement), the Issuer may redeem the 2028 Notes in whole (but not in part) at any time, at a price equal to 100% of their principal amount plus accrued and unpaid interest to, but excluding, the redemption date.

     

    2

     

     

    Payment of Additional Amounts: In the event that the Issuer is required to withhold or deduct from payments on the Notes taxes imposed by Switzerland or another Relevant Taxing Jurisdiction, the Issuer will, subject to certain exceptions, pay such additional amounts as will result, after withholding or deduction of such taxes, in the receipt by the holders of the amounts that would have been received had no withholding or deduction been required. Notwithstanding the foregoing, the Issuer shall not be required to pay any additional amounts with respect to any withholding taxes imposed by the United States or by any political subdivision, territory or possession thereof.
       
    CUSIP: 66989HAX6
       
    ISIN: US66989HAX61
       
    Trade Date: November 3, 2025
       
    Expected Settlement Date:* November 5, 2025 (T+2)
       
    Listing: None
       
    Anticipated Ratings:** Aa3 by Moody’s Ratings
    AA- by S&P Global Ratings
       
    Joint Book-Running Managers: BofA Securities, Inc.
    HSBC Securities (USA) Inc.
    J.P. Morgan Securities LLC
    BNP Paribas Securities Corp.
    Deutsche Bank Securities Inc.
    SG Americas Securities, LLC
       
    Co-Managers: Citigroup Global Markets Inc.
    Mizuho Securities USA LLC

     

    3

     

     

    4.100% Notes due 2030 (the "2030 Notes”):  
       
    Issuer: Novartis Capital Corporation
       
    Guarantor: Novartis AG
       
    Size: $1,750,000,000
       
    Maturity Date: November 5, 2030
       
    Coupon: 4.100%
       
    Interest Payment Dates: May 5 and November 5, commencing May 5, 2026
       
    Price to Public: 99.700%
       
    Benchmark Treasury: 3.625% due October 31, 2030
       
    Benchmark Treasury Price and Yield: 99-18 3/4 / 3.717%
       
    Spread to Benchmark Treasury: 45 bps
       
    Yield: 4.167%
       
    Optional Redemption: Prior to October 5, 2030 (the date that is one month prior to the scheduled maturity date of the 2030 Notes) (the "2030 Par Call Date”), we may redeem the 2030 Notes, in whole or in part, at our option, at any time and from time to time at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:
       
        (1) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the 2030 Notes matured on the 2030 Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 7.5 bps, less (b) interest accrued to the date of redemption, and

     

    4

     

     

        (2) 100% of the principal amount of the 2030 Notes to be redeemed,
       
      plus, in either case, accrued and unpaid interest thereon to the redemption date.
       
      On or after the 2030 Par Call Date we may redeem the 2030 Notes, in whole or in part, at any time and from time to time at a redemption price equal to 100% of the principal amount of the 2030 Notes to be redeemed on the applicable redemption date plus accrued and unpaid interest thereon to the redemption date.
       
    Optional Redemption for Tax Reasons: In the event of changes in withholding taxes applicable to payments under or with respect to the 2030 Notes or certain intercompany loans in Switzerland or another Relevant Taxing Jurisdiction (as defined and provided for in the prospectus supplement), the Issuer may redeem the 2030 Notes in whole (but not in part) at any time, at a price equal to 100% of their principal amount plus accrued and unpaid interest to, but excluding, the redemption date.
       
    Payment of Additional Amounts: In the event that the Issuer is required to withhold or deduct from payments on the Notes taxes imposed by Switzerland or another Relevant Taxing Jurisdiction, the Issuer will, subject to certain exceptions, pay such additional amounts as will result, after withholding or deduction of such taxes, in the receipt by the holders of the amounts that would have been received had no withholding or deduction been required. Notwithstanding the foregoing, the Issuer shall not be required to pay any additional amounts with respect to any withholding taxes imposed by the United States or by any political subdivision, territory or possession thereof.
       
    CUSIP: 66989HAY4
       
    ISIN: US66989HAY45
       
    Trade Date: November 3, 2025

     

    5

     

     

    Expected Settlement Date:* November 5, 2025 (T+2)
       
    Listing: None
       
    Anticipated Ratings:** Aa3 by Moody’s Ratings
    AA- by S&P Global Ratings
       
    Joint Book-Running Managers: BofA Securities, Inc.
    HSBC Securities (USA) Inc.
    J.P. Morgan Securities LLC
    BNP Paribas Securities Corp.
    Deutsche Bank Securities Inc.
    SG Americas Securities, LLC
       
    Co-Managers: Citigroup Global Markets Inc.
    Mizuho Securities USA LLC

     

    6

     

     

    4.300% Notes due 2032 (the “2032 Notes”):  
       
    Issuer: Novartis Capital Corporation
       
    Guarantor: Novartis AG
       
    Size: $925,000,000
       
    Maturity Date: November 5, 2032
       
    Coupon: 4.300%
       
    Interest Payment Dates: May 5 and November 5, commencing May 5, 2026
       
    Price to Public: 99.409%
       
    Benchmark Treasury: 3.750% due October 31, 2032
       
    Benchmark Treasury Price and Yield: 99-03 / 3.899%
       
    Spread to Benchmark Treasury: 50 bps
       
    Yield: 4.399%
       
    Optional Redemption: Prior to September 5, 2032 (the date that is two months prior to the scheduled maturity date of the 2032 Notes) (the "2032 Par Call Date”), we may redeem the 2032 Notes, in whole or in part, at our option, at any time and from time to time at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:
       
        (1) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the 2032 Notes matured on the 2032 Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 7.5 bps, less (b) interest accrued to the date of redemption, and

     

    7

     

     

        (2) 100% of the principal amount of the 2032 Notes to be redeemed,
       
      plus, in either case, accrued and unpaid interest thereon to the redemption date.
       
      On or after the 2032 Par Call Date we may redeem the 2032 Notes, in whole or in part, at any time and from time to time at a redemption price equal to 100% of the principal amount of the 2032 Notes to be redeemed on the applicable redemption date plus accrued and unpaid interest thereon to the redemption date.
       
    Optional Redemption for Tax Reasons: In the event of changes in withholding taxes applicable to payments under or with respect to the 2032 Notes or certain intercompany loans in Switzerland or another Relevant Taxing Jurisdiction (as defined and provided for in the prospectus supplement), the Issuer may redeem the 2032 Notes in whole (but not in part) at any time, at a price equal to 100% of their principal amount plus accrued and unpaid interest to, but excluding, the redemption date.
       
    Payment of Additional Amounts: In the event that the Issuer is required to withhold or deduct from payments on the Notes taxes imposed by Switzerland or another Relevant Taxing Jurisdiction, the Issuer will, subject to certain exceptions, pay such additional amounts as will result, after withholding or deduction of such taxes, in the receipt by the holders of the amounts that would have been received had no withholding or deduction been required. Notwithstanding the foregoing, the Issuer shall not be required to pay any additional amounts with respect to any withholding taxes imposed by the United States or by any political subdivision, territory or possession thereof.
       
    CUSIP: 66989HAZ1
       
    ISIN: US66989HAZ10

     

    8

     

     

    Trade Date: November 3, 2025
       
    Expected Settlement Date:* November 5, 2025 (T+2)
       
    Listing: None
       
    Anticipated Ratings:** Aa3 by Moody’s Ratings
    AA- by S&P Global Ratings
       
    Joint Book-Running Managers: BofA Securities, Inc.
    HSBC Securities (USA) Inc.
    J.P. Morgan Securities LLC
    BNP Paribas Securities Corp.
    Deutsche Bank Securities Inc.
    SG Americas Securities, LLC
       
    Co-Managers: Citigroup Global Markets Inc.
    Mizuho Securities USA LLC

     

    9

     

     

    4.600% Notes due 2035 (the “2035 Notes”):  
       
    Issuer: Novartis Capital Corporation
       
    Guarantor: Novartis AG
       
    Size: $925,000,000
       
    Maturity Date: November 5, 2035
       
    Coupon: 4.600%
       
    Interest Payment Dates: May 5 and November 5, commencing May 5, 2026
       
    Price to Public: 99.564%
       
    Benchmark Treasury: 4.250% due August 15, 2035
       
    Benchmark Treasury Price and Yield: 101-05 / 4.105%
       
    Spread to Benchmark Treasury: 55 bps
       
    Yield: 4.655%
       
    Optional Redemption: Prior to August 5, 2035 (the date that is three months prior to the scheduled maturity date of the 2035 Notes) (the “2035 Par Call Date”), we may redeem the 2035 Notes, in whole or in part, at our option, at any time and from time to time at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:
       
        (1) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the 2035 Notes matured on the 2035 Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 10 bps, less (b) interest accrued to the date of redemption, and

     

    10

     

     

        (2) 100% of the principal amount of the 2035 Notes to be redeemed,
       
      plus, in either case, accrued and unpaid interest thereon to the redemption date.
       
      On or after the 2035 Par Call Date we may redeem the 2035 Notes, in whole or in part, at any time and from time to time at a redemption price equal to 100% of the principal amount of the 2035 Notes to be redeemed on the applicable redemption date plus accrued and unpaid interest thereon to the redemption date.
       
    Optional Redemption for Tax Reasons: In the event of changes in withholding taxes applicable to payments under or with respect to the 2035 Notes or certain intercompany loans in Switzerland or another Relevant Taxing Jurisdiction (as defined and provided for in the prospectus supplement), the Issuer may redeem the 2035 Notes in whole (but not in part) at any time, at a price equal to 100% of their principal amount plus accrued and unpaid interest to, but excluding, the redemption date.
       
    Payment of Additional Amounts: In the event that the Issuer is required to withhold or deduct from payments on the Notes taxes imposed by Switzerland or another Relevant Taxing Jurisdiction, the Issuer will, subject to certain exceptions, pay such additional amounts as will result, after withholding or deduction of such taxes, in the receipt by the holders of the amounts that would have been received had no withholding or deduction been required. Notwithstanding the foregoing, the Issuer shall not be required to pay any additional amounts with respect to any withholding taxes imposed by the United States or by any political subdivision, territory or possession thereof.
       
    CUSIP: 66989HBA5
       
    ISIN: US66989HBA59

     

    11

     

     

    Trade Date: November 3, 2025
       
    Expected Settlement Date:* November 5, 2025 (T+2)
       
    Listing: None
       
    Anticipated Ratings:** Aa3 by Moody’s Ratings
    AA- by S&P Global Ratings
       
    Joint Book-Running Managers: BofA Securities, Inc.
    HSBC Securities (USA) Inc.
    J.P. Morgan Securities LLC
    BNP Paribas Securities Corp.
    Deutsche Bank Securities Inc.
    SG Americas Securities, LLC
       
    Co-Managers: Citigroup Global Markets Inc.
    Mizuho Securities USA LLC

     

    12

     

     

    5.200% Notes due 2045 (the “2045 Notes”):  
       
    Issuer: Novartis Capital Corporation
       
    Guarantor: Novartis AG
       
    Size: $350,000,000
       
    Maturity Date: November 5, 2045
       
    Coupon: 5.200%
       
    Interest Payment Dates: May 5 and November 5, commencing May 5, 2026
       
    Price to Public: 99.889%
       
    Benchmark Treasury: 4.875% due August 15, 2045
       
    Benchmark Treasury Price and Yield: 102-24+ / 4.659%
       
    Spread to Benchmark Treasury: 55 bps
       
    Yield: 5.209%
       
    Optional Redemption: Prior to May 5, 2045 (the date that is six months prior to the scheduled maturity date of the 2045 Notes) (the “2045 Par Call Date”), we may redeem the 2045 Notes, in whole or in part, at our option, at any time and from time to time at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:
       
        (1) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the 2045 Notes matured on the 2045 Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 10 bps, less (b) interest accrued to the date of redemption, and

     

    13

     

     

        (2) 100% of the principal amount of the 2045 Notes to be redeemed,
           
      plus, in either case, accrued and unpaid interest thereon to the redemption date.
       
      On or after the 2045 Par Call Date we may redeem the 2045 Notes, in whole or in part, at any time and from time to time at a redemption price equal to 100% of the principal amount of the 2045 Notes to be redeemed on the applicable redemption date plus accrued and unpaid interest thereon to the redemption date.
       
    Optional Redemption for Tax Reasons: In the event of changes in withholding taxes applicable to payments under or with respect to the 2045 Notes or certain intercompany loans in Switzerland or another Relevant Taxing Jurisdiction (as defined and provided for in the prospectus supplement), the Issuer may redeem the 2045 Notes in whole (but not in part) at any time, at a price equal to 100% of their principal amount plus accrued and unpaid interest to, but excluding, the redemption date.
       
    Payment of Additional Amounts: In the event that the Issuer is required to withhold or deduct from payments on the Notes taxes imposed by Switzerland or another Relevant Taxing Jurisdiction, the Issuer will, subject to certain exceptions, pay such additional amounts as will result, after withholding or deduction of such taxes, in the receipt by the holders of the amounts that would have been received had no withholding or deduction been required. Notwithstanding the foregoing, the Issuer shall not be required to pay any additional amounts with respect to any withholding taxes imposed by the United States or by any political subdivision, territory or possession thereof.
       
    CUSIP: 66989HBB3
       
    ISIN: US66989HBB33

     

    14

     

     

    Trade Date: November 3, 2025
       
    Expected Settlement Date:* November 5, 2025 (T+2)
       
    Listing: None
       
    Anticipated Ratings:** Aa3 by Moody’s Ratings
    AA- by S&P Global Ratings
       
    Joint Book-Running Managers: BofA Securities, Inc.
    HSBC Securities (USA) Inc.
    J.P. Morgan Securities LLC
    BNP Paribas Securities Corp.
    Deutsche Bank Securities Inc.
    SG Americas Securities, LLC
       
    Co-Managers: Citigroup Global Markets Inc.
    Mizuho Securities USA LLC

     

    15

     

     

    5.300% Notes due 2055 (the “2055 Notes”):  
       
    Issuer: Novartis Capital Corporation
       
    Guarantor: Novartis AG
       
    Size: $550,000,000
       
    Maturity Date: November 5, 2055
       
    Coupon: 5.300%
       
    Interest Payment Dates: May 5 and November 5, commencing May 5, 2026
       
    Price to Public: 99.464%
       
    Benchmark Treasury: 4.750% due May 15, 2055
       
    Benchmark Treasury Price and Yield: 101-00+ / 4.686%
       
    Spread to Benchmark Treasury: 65 bps
       
    Yield: 5.336%
       
    Optional Redemption: Prior to May 5, 2055 (the date that is six months prior to the scheduled maturity date of the 2055 Notes) (the “2055 Par Call Date”), we may redeem the 2055 Notes, in whole or in part, at our option, at any time and from time to time at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:
       
        (1) (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the 2055 Notes matured on the 2055 Par Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 10 bps, less (b) interest accrued to the date of redemption, and

     

    16

     

     

        (2) 100% of the principal amount of the 2055 Notes to be redeemed,
       
      plus, in either case, accrued and unpaid interest thereon to the redemption date.
       
      On or after the 2055 Par Call Date we may redeem the 2055 Notes, in whole or in part, at any time and from time to time at a redemption price equal to 100% of the principal amount of the 2055 Notes to be redeemed on the applicable redemption date plus accrued and unpaid interest thereon to the redemption date.
       
    Optional Redemption for Tax Reasons: In the event of changes in withholding taxes applicable to payments under or with respect to the 2055 Notes or certain intercompany loans in Switzerland or another Relevant Taxing Jurisdiction (as defined and provided for in the prospectus supplement), the Issuer may redeem the 2055 Notes in whole (but not in part) at any time, at a price equal to 100% of their principal amount plus accrued and unpaid interest to, but excluding, the redemption date.
       
    Payment of Additional Amounts: In the event that the Issuer is required to withhold or deduct from payments on the Notes taxes imposed by Switzerland or another Relevant Taxing Jurisdiction, the Issuer will, subject to certain exceptions, pay such additional amounts as will result, after withholding or deduction of such taxes, in the receipt by the holders of the amounts that would have been received had no withholding or deduction been required. Notwithstanding the foregoing, the Issuer shall not be required to pay any additional amounts with respect to any withholding taxes imposed by the United States or by any political subdivision, territory or possession thereof.  
       
    CUSIP: 66989HBC1
       
    ISIN: US66989HBC16

     

    17

     

     

    Trade Date: November 3, 2025
       
    Expected Settlement Date:* November 5, 2025 (T+2)
       
    Listing: None
       
    Anticipated Ratings:** Aa3 by Moody’s Ratings
    AA- by S&P Global Ratings
       
    Joint Book-Running Managers: BofA Securities, Inc.
    HSBC Securities (USA) Inc.
    J.P. Morgan Securities LLC
    BNP Paribas Securities Corp.
    Deutsche Bank Securities Inc.
    SG Americas Securities, LLC
       
    Co-Managers: Citigroup Global Markets Inc.
    Mizuho Securities USA LLC

     

    18

     

     

    Floating Rate Notes due 2028 (the “Floating Rate Notes”):  
       
    Issuer: Novartis Capital Corporation
       
    Guarantor: Novartis AG
       
    Size: $800,000,000
       
    Maturity Date: November 5, 2028
       
    Interest Rate Basis: Compounded SOFR
       
    Spread to Compounded SOFR: 52 bps
       
    Floating Rate Interest Payment Dates: February 5, May 5, August 5 and November 5, of each year, commencing February 5, 2026
       
    Interest Reset Dates: Each Floating Rate Interest Payment Date
       
    Initial Interest Rate: The initial interest rate will be Compounded SOFR determined on February 3, 2026, plus 0.52%.
       
    Interest Determination Date: The second U.S. Government Securities Business Day (as defined in the prospectus supplement) preceding each Floating Rate Interest Payment Date.
       
    Initial Interest Period: The period from and including November 5, 2025 to, but excluding the first Floating Rate Interest Payment Date.
       
    Interest Period: The period from and including a Floating Rate Interest Payment Date to, but excluding, the immediately succeeding Floating Rate Interest Payment Date provided that the final Interest Period for the floating rate notes will be the period from and including the Floating Rate Interest Payment Date immediately preceding the maturity date of the floating rate notes to, but excluding, the maturity date.
       
    Observation Period: In respect of each Interest Period, the period from and including two U.S. Government Securities Business Days preceding the first date of such relevant Interest Period to but excluding two U.S. Government Securities Business Days preceding the Latter Floating Rate Interest Payment Date (as defined in the prospectus supplement) for such Interest Period (or in the final Interest Period, preceding the maturity date); provided that the first Observation Period shall be the period from and including two U.S. Government Securities Business Days preceding the settlement date of the floating rate notes to, but excluding, the two U.S. Government Securities Business Days preceding the first Floating Rate Interest Payment Date.

     

    19

     

     

    Optional Redemption: Not applicable.
       
    Optional Redemption for Tax Reasons: In the event of changes in withholding taxes applicable to payments under or with respect to the Floating Rate Notes or certain intercompany loans in Switzerland or another Relevant Taxing Jurisdiction (as defined and provided for in the prospectus supplement), the Issuer may redeem the Floating Rate Notes in whole (but not in part) at any time, at a price equal to 100% of their principal amount plus accrued and unpaid interest to, but excluding, the redemption date.
       
    Payment of Additional Amounts: In the event that the Issuer is required to withhold or deduct from payments on the Notes taxes imposed by Switzerland or another Relevant Taxing Jurisdiction, the Issuer will, subject to certain exceptions, pay such additional amounts as will result, after withholding or deduction of such taxes, in the receipt by the holders of the amounts that would have been received had no withholding or deduction been required. Notwithstanding the foregoing, the Issuer shall not be required to pay any additional amounts with respect to any withholding taxes imposed by the United States or by any political subdivision, territory or possession thereof.
       
    Price to Public: 100.000%

     

    20

     

     

    CUSIP: 66989HBD9
       
    ISIN: US66989HBD98
       
    Calculation Agent: HSBC Bank USA, National Association
       
    Trade Date: November 3, 2025
       
    Expected Settlement Date:* November 5, 2025 (T+2)
       
    Listing: None
       
    Anticipated Ratings:** Aa3 by Moody’s Ratings
    AA- by S&P Global Ratings
       
    Joint Book-Running Managers: BofA Securities, Inc.
    HSBC Securities (USA) Inc.
    J.P. Morgan Securities LLC
    BNP Paribas Securities Corp.
    Deutsche Bank Securities Inc.
    SG Americas Securities, LLC
       
    Co-Managers: Citigroup Global Markets Inc.
    Mizuho Securities USA LLC

     

    * Note: Under Rule 15c6-1 under the Securities Exchange Act of 1934, trades in the secondary market generally are required to settle in one business day, unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the 2028 Notes, the 2030 Notes, the 2032 Notes, the 2035 Notes, the 2045 Notes, the 2055 Notes or the Floating Rate Notes (collectively, the “Notes”) on the date hereof will be required, by virtue of the fact that the Notes initially will not settle in T+1, to specify an alternate settlement cycle at the time of any such trade to prevent a failed settlement. Purchasers of the Notes who wish to trade such Notes on the date of pricing of the Notes sold in this offering should consult their own advisor.

     

    ** Note: A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or withdrawal at any time.

     

    The issuer and the guarantor have filed a registration statement (including a prospectus and a prospectus supplement) with the Securities and Exchange Commission (the “SEC”) for the offering to which this communication relates. Before you invest, you should read the prospectus supplement and the accompanying prospectus in that registration statement and other documents the issuer and the guarantor have filed with the SEC for more complete information about the issuer, the guarantor and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the offering will arrange to send you the prospectus supplement and the accompanying prospectus if you request it by calling BofA Securities, Inc. at +1-800-294-1322, HSBC Securities (USA) Inc. at +1-866-811-8049 or J.P. Morgan Securities LLC at +1-212-834-4533.

     

    ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER E-MAIL SYSTEM.

     

    21

     

    Get the next $NVS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NVS

    DatePrice TargetRatingAnalyst
    9/12/2025$118.00Neutral → Sell
    Goldman
    8/8/2025$123.00Underweight → Equal-Weight
    Morgan Stanley
    2/13/2025Buy → Neutral
    UBS
    2/12/2025Underweight
    Morgan Stanley
    2/4/2025Hold → Buy
    Deutsche Bank
    12/4/2024Hold → Reduce
    HSBC Securities
    9/11/2024$135.00 → $130.00Buy → Neutral
    BofA Securities
    9/5/2024Buy → Neutral
    Goldman
    More analyst ratings

    $NVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Novartis AG downgraded by Goldman with a new price target

    Goldman downgraded Novartis AG from Neutral to Sell and set a new price target of $118.00

    9/12/25 7:50:34 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novartis AG upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Novartis AG from Underweight to Equal-Weight and set a new price target of $123.00

    8/8/25 7:57:50 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novartis AG downgraded by UBS

    UBS downgraded Novartis AG from Buy to Neutral

    2/13/25 8:48:14 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVS
    SEC Filings

    View All

    SEC Form FWP filed by Novartis AG

    FWP - NOVARTIS AG (0001114448) (Subject)

    11/3/25 8:59:48 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novartis AG

    6-K - NOVARTIS AG (0001114448) (Filer)

    10/28/25 6:07:00 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novartis AG

    6-K - NOVARTIS AG (0001114448) (Filer)

    10/27/25 6:06:16 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVS
    Leadership Updates

    Live Leadership Updates

    View All

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

    11/5/24 7:00:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $NVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Novartis AG

    SC 13D/A - NOVARTIS AG (0001114448) (Filed by)

    10/17/24 4:01:28 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 1, 2024 - FDA Roundup: November 1, 2024

    For Immediate Release: November 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “FDA Takes Exciting Steps Toward Establishing the Rare Disease Innovation Hub,” by Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER) and Peter Marks, M.D., Ph.D., director

    11/1/24 3:18:19 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

    NetworkNewsWire Editorial Coverage NEW YORK, Oct. 27, 2025 /PRNewswire/ -- The global oncology market is rapidly shifting toward smarter drug-delivery systems that enhance efficacy, reduce toxicity and improve patient outcomes. Traditional oral or IV drugs often face poor bioavailability and limited tumor targeting — a major bottleneck in cancer treatment success. Recent breakthroughs in nanomedicine are making headlines, as the FDA and global regulatory bodies increasingly endorse nanocarrier-based delivery for complex drugs. This surge underscores a larger industry trend: the race to improve how drugs reach and act within the body. Oncotelic Therapeutics Inc.'s (OTCQB:OTLC) (profile) Decip

    10/27/25 8:30:00 AM ET
    $BCAX
    $IOBT
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Next-Generation Targeted Therapies Reshape Precision Oncology Landscape

    USA News Group News Commentary –Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 15, 2025 /PRNewswire/ -- USA News Group News Commentary – Biomarker-driven drug development is accelerating across oncology as companies advance novel mechanisms targeting previously difficult-to-treat patient populations. The cancer immunotherapy market reached $226 billion in 2024 and continues expanding rapidly, driven by precision approaches that pair targeted agents with immunotherapy, identify genetic vulnerabilities, and deploy radioligand therapies for metastatic disease[1]. Recent clinical data demonstrating high response rates in biomarker-selected populations underscore the shift toward mole

    10/15/25 9:11:00 AM ET
    $GTBP
    $IDYA
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

    Rhapsido helps to inhibit release of histamine and proinflammatory mediators by targeting BTK, offering unique approach to CSU treatment1Well-controlled disease observed as fast as two weeks, with demonstrated safety profile that requires no lab monitoring11.7 million people in US live with CSU; more than half remain symptomatic despite increasing doses of antihistamines2,3Remibrutinib also in clinical development for chronic inducible urticaria, food allergy, and hidradenitis suppurativa, expanding Novartis Immunology portfolioEAST HANOVER, N.J., Sept. 30, 2025 /PRNewswire/ -- Novartis announced today that Rhapsido® (remibrutinib) received US Food and Drug Administration (FDA) approval as a

    9/30/25 5:23:00 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NVS
    Financials

    Live finance-specific insights

    View All

    PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

    - PTC to receive $1.0B in cash at closing -- PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones -- PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales -- Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study -- PTC will host a conference call on Dec. 2, 2024, at 8:30 am EST- WARREN, N.J., Dec. 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NY

    12/2/24 7:00:00 AM ET
    $NVS
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Just - Evotec Biologics Launches Tech Partnership for Biosimilars Development and Commercial Manufacturing

    JUST - EVOTEC BIOLOGICS AND SANDOZ JOIN FORCES TO DEVELOP AND MANUFACTURE A DEFINED PORTFOLIO OF BIOSIMILAR MOLECULESJUST - EVOTEC BIOLOGICS TO RECEIVE DOUBLE-DIGIT-MILLION UPFRONT, FUTURE PAYMENTS DEPENDENT ON SUCCESSFUL DEVELOPMENT PROGRESS OF US$ 640 M, ADDITIONAL UNDISCLOSED PAYMENTS DEPENDENT ON PROGRESS INTO COMMERCIAL MANUFACTURING AND EXERCISING THE S.POD OPTIONTHE PARTNERSHIP ASPIRES TO DISRUPT THE BIOSIMILARS MARKET WITH AFFORDABLE AND ACCESSIBLE HIGHEST-QUALITY MEDICINES FOR PATIENTS ACROSS THE GLOBETHE PARTNERSHIP IS FOUNDED ON JUST - EVOTEC BIOLOGICS' AI-DRIVEN, FULLY INTEGRATED TECH PLATFORM AND CONTINUOUS MANUFACTURING COMBINED WITH SANDOZ' LEADING BIOSIMILARS PIPELINE AND CAP

    5/9/23 2:30:00 PM ET
    $EVO
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ligand Reports First Quarter 2023 Financial Results

    2023 Financial Guidance Raised Conference Call Begins at 4:30 p.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management will host a conference call today beginning at 4:30 p.m. Eastern time to discuss this announcement and answer questions. "2023 is off to a strong start with $44.0 million in first quarter revenues driven by the continued growth of our royalty revenue and the approval milestone from Travere's FILSPARI for the treatment of IgA nephropathy," said Todd Davis, CEO of Ligand. "We have several partner catalyst

    5/4/23 4:01:00 PM ET
    $ANEB
    $LGND
    $NOVN
    Biotechnology: Pharmaceutical Preparations
    Health Care